Artículos de revistas sobre el tema "Antiviral inhibitors"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Antiviral inhibitors".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Frederickson, Robert. "Antiviral protease inhibitors". Nature Biotechnology 17, n.º 12 (diciembre de 1999): 1150. http://dx.doi.org/10.1038/70677.
Texto completoWang, Q. May, Robert B. Johnson, Louis N. Jungheim, Jeffrey D. Cohen y Elcira C. Villarreal. "Dual Inhibition of Human Rhinovirus 2A and 3C Proteases by Homophthalimides". Antimicrobial Agents and Chemotherapy 42, n.º 4 (1 de abril de 1998): 916–20. http://dx.doi.org/10.1128/aac.42.4.916.
Texto completoMello, Chris, Esmeralda Aguayo, Madeleine Rodriguez, Gary Lee, Robert Jordan, Tomas Cihlar y Gabriel Birkus. "Multiple Classes of Antiviral Agents ExhibitIn VitroActivity against Human Rhinovirus Type C". Antimicrobial Agents and Chemotherapy 58, n.º 3 (23 de diciembre de 2013): 1546–55. http://dx.doi.org/10.1128/aac.01746-13.
Texto completoVinson, Valda. "Promising antiviral protease inhibitors". Science 368, n.º 6497 (18 de junio de 2020): 1324.2–1324. http://dx.doi.org/10.1126/science.368.6497.1324-b.
Texto completoMorales Vasquez, Desarey, Jun-Gyu Park, Ginés Ávila-Pérez, Aitor Nogales, Juan Carlos de la Torre, Fernando Almazan y Luis Martinez-Sobrido. "Identification of Inhibitors of ZIKV Replication". Viruses 12, n.º 9 (18 de septiembre de 2020): 1041. http://dx.doi.org/10.3390/v12091041.
Texto completoSepúlveda, Claudia Soledad, Cybele Carina García y Elsa Beatriz Damonte. "Inhibitors of Nucleotide Biosynthesis as Candidates for a Wide Spectrum of Antiviral Chemotherapy". Microorganisms 10, n.º 8 (12 de agosto de 2022): 1631. http://dx.doi.org/10.3390/microorganisms10081631.
Texto completoDe Nicolò, Amedeo, Marco Simiele, Andrea Calcagno, Adnan Mohamed Abdi, Stefano Bonora, Giovanni Di Perri y Antonio D'Avolio. "Intracellular Antiviral Activity of Low-Dose Ritonavir in Boosted Protease Inhibitor Regimens". Antimicrobial Agents and Chemotherapy 58, n.º 7 (5 de mayo de 2014): 4042–47. http://dx.doi.org/10.1128/aac.00104-14.
Texto completoHolý, Antonín, Ivan Votruba y Erik De Clercq. "Structure-activity studies on open-chain analogues of nucleosides: Inhibition of S-adenosyl-L-homocysteine hydrolase and antiviral activity 1. Neutral open-chain analogues". Collection of Czechoslovak Chemical Communications 50, n.º 1 (1985): 245–61. http://dx.doi.org/10.1135/cccc19850245.
Texto completoHewajuli, Dyah Ayu y NLPI Dharmayanti. "Efficacy, Mechanism and Antiviral Resistance of Neuraminidase Inhibitors and Adamantane against Avian Influenza". Indonesian Bulletin of Animal and Veterinary Sciences 29, n.º 2 (4 de diciembre de 2019): 61. http://dx.doi.org/10.14334/wartazoa.v29i2.1951.
Texto completoHayden, Frederick G. "Perspectives on antiviral use during pandemic influenza". Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 356, n.º 1416 (29 de diciembre de 2001): 1877–84. http://dx.doi.org/10.1098/rstb.2001.1007.
Texto completoCanal, Berta, Allison W. McClure, Joseph F. Curran, Mary Wu, Rachel Ulferts, Florian Weissmann, Jingkun Zeng et al. "Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease". Biochemical Journal 478, n.º 13 (2 de julio de 2021): 2445–64. http://dx.doi.org/10.1042/bcj20210198.
Texto completoKoban, Robert, Markus Neumann, Philipp P. Nelson y Heinz Ellerbrok. "Differential Efficacy of Novel Antiviral Substances in 3D and Monolayer Cell Culture". Viruses 12, n.º 11 (12 de noviembre de 2020): 1294. http://dx.doi.org/10.3390/v12111294.
Texto completoÁlvarez-Fernández, Hadrián, Patricia Mingo-Casas, Ana-Belén Blázquez, Flavia Caridi, Juan Carlos Saiz, María-Jesús Pérez-Pérez, Miguel A. Martín-Acebes y Eva-María Priego. "Allosteric Inhibition of Neutral Sphingomyelinase 2 (nSMase2) by DPTIP: From Antiflaviviral Activity to Deciphering Its Binding Site through In Silico Studies and Experimental Validation". International Journal of Molecular Sciences 23, n.º 22 (11 de noviembre de 2022): 13935. http://dx.doi.org/10.3390/ijms232213935.
Texto completoEltahla, Auda A., Kun Lee Lim, John-Sebastian Eden, Andrew G. Kelly, Jason M. Mackenzie y Peter A. White. "Nonnucleoside Inhibitors of Norovirus RNA Polymerase: Scaffolds for Rational Drug Design". Antimicrobial Agents and Chemotherapy 58, n.º 6 (17 de marzo de 2014): 3115–23. http://dx.doi.org/10.1128/aac.02799-13.
Texto completoAsahchop, Eugene L., Mark A. Wainberg, Richard D. Sloan y Cécile L. Tremblay. "Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors". Antimicrobial Agents and Chemotherapy 56, n.º 10 (25 de junio de 2012): 5000–5008. http://dx.doi.org/10.1128/aac.00591-12.
Texto completoMa, Ling, Jiajia Wen, Biao Dong, Jinming Zhou, Shangjiu Hu, Juxian Wang, Yucheng Wang, Mei Zhu y Shan Cen. "Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants". International Journal of Molecular Sciences 23, n.º 22 (16 de noviembre de 2022): 14178. http://dx.doi.org/10.3390/ijms232214178.
Texto completoLangendries, Lana, Rana Abdelnabi, Johan Neyts y Leen Delang. "Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors". Microorganisms 9, n.º 4 (31 de marzo de 2021): 734. http://dx.doi.org/10.3390/microorganisms9040734.
Texto completoSacco, Michael Dominic, Chunlong Ma, Panagiotis Lagarias, Ang Gao, Julia Alma Townsend, Xiangzhi Meng, Peter Dube et al. "Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L". Science Advances 6, n.º 50 (6 de noviembre de 2020): eabe0751. http://dx.doi.org/10.1126/sciadv.abe0751.
Texto completoGudima, Georgii, Ilya Kofiadi, Igor Shilovskiy, Dmitry Kudlay y Musa Khaitov. "Antiviral Therapy of COVID-19". International Journal of Molecular Sciences 24, n.º 10 (16 de mayo de 2023): 8867. http://dx.doi.org/10.3390/ijms24108867.
Texto completoPatick, A. K. y K. E. Potts. "Protease Inhibitors as Antiviral Agents". Clinical Microbiology Reviews 11, n.º 4 (1 de octubre de 1998): 614–27. http://dx.doi.org/10.1128/cmr.11.4.614.
Texto completoAlymova, I., G. Taylor y A. Portner. "Neuraminidase Inhibitors as Antiviral Agents". Current Drug Target -Infectious Disorders 5, n.º 4 (1 de diciembre de 2005): 401–9. http://dx.doi.org/10.2174/156800505774912884.
Texto completoPeel, Michael y Andrew Scribner. "Cyclophilin inhibitors as antiviral agents". Bioorganic & Medicinal Chemistry Letters 23, n.º 16 (agosto de 2013): 4485–92. http://dx.doi.org/10.1016/j.bmcl.2013.05.101.
Texto completoLee, Wei-Ping, Keng-Li Lan, Shi-Xian Liao, Yi-Hsiang Huang, Ming-Chih Hou y Keng-Hsin Lan. "Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus". American Journal of Chinese Medicine 46, n.º 04 (enero de 2018): 835–52. http://dx.doi.org/10.1142/s0192415x18500441.
Texto completoMilligan, Jennifer C., Theresa U. Zeisner, George Papageorgiou, Dhira Joshi, Christelle Soudy, Rachel Ulferts, Mary Wu et al. "Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease". Biochemical Journal 478, n.º 13 (2 de julio de 2021): 2499–515. http://dx.doi.org/10.1042/bcj20210197.
Texto completoMcFadden, Karyn, Patricia Fletcher, Fiorella Rossi, Kantharaju, Muddagowda Umashankara, Vanessa Pirrone, Srivats Rajagopal et al. "Antiviral Breadth and Combination Potential of Peptide Triazole HIV-1 Entry Inhibitors". Antimicrobial Agents and Chemotherapy 56, n.º 2 (14 de noviembre de 2011): 1073–80. http://dx.doi.org/10.1128/aac.05555-11.
Texto completoWulandari, Dwi y T. Mirawati Sudiro. "PENGEMBANGAN ANTIVIRUS HUMAN PAPILLOMA VIRUS BERBASIS MOLEKUL KECIL". Majalah Kedokteran Andalas 37, n.º 1 (3 de mayo de 2015): 58. http://dx.doi.org/10.22338/mka.v37.i1.p58-63.2014.
Texto completoIshii, H., M. Hasobe, J. G. McKee, D. B. Ault-Riché y R. T. Borchardt. "Synergistic Antiviral Activity of Inhibitors of S-Adenosylhomocysteine Hydrolase and Ribavirin". Antiviral Chemistry and Chemotherapy 4, n.º 2 (abril de 1993): 127–30. http://dx.doi.org/10.1177/095632029300400207.
Texto completoTremblay, Cécile L., Françoise Giguel, Christopher Kollmann, Yongbiao Guan, Ting-Chao Chou, Bahige M. Baroudy y Martin S. Hirsch. "Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro". Antimicrobial Agents and Chemotherapy 46, n.º 5 (mayo de 2002): 1336–39. http://dx.doi.org/10.1128/aac.46.5.1336-1339.2002.
Texto completoGanter, Benedikt, Martin Zickler, Johanna Huchting, Matthias Winkler, Anna Lüttjohann, Chris Meier, Gülsah Gabriel y Sebastian Beck. "T-705-Derived Prodrugs Show High Antiviral Efficacies against a Broad Range of Influenza A Viruses with Synergistic Effects When Combined with Oseltamivir". Pharmaceutics 15, n.º 6 (14 de junio de 2023): 1732. http://dx.doi.org/10.3390/pharmaceutics15061732.
Texto completoMathy, Joanna E., Sue Ma, Teresa Compton y Kai Lin. "Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of Resistance". Antimicrobial Agents and Chemotherapy 52, n.º 9 (30 de junio de 2008): 3267–75. http://dx.doi.org/10.1128/aac.00498-08.
Texto completoSumalapao, Derick Erl P. "Elucidation on the Physicochemical Properties of Potential and Clinically Approved Antiviral Drugs: A Search for Effective Therapies against SARS-CoV-2 Infection". Journal of Pure and Applied Microbiology 14, suppl 1 (22 de mayo de 2020): 1025–34. http://dx.doi.org/10.22207/jpam.14.spl1.41.
Texto completoRocha-Pereira, J., M. S. J. Nascimento, Q. Ma, R. Hilgenfeld, J. Neyts y D. Jochmans. "The Enterovirus Protease Inhibitor Rupintrivir Exerts Cross-Genotypic Anti-Norovirus Activity and Clears Cells from the Norovirus Replicon". Antimicrobial Agents and Chemotherapy 58, n.º 8 (2 de junio de 2014): 4675–81. http://dx.doi.org/10.1128/aac.02546-13.
Texto completoKausar, Shamaila, Fahad Said Khan, Muhammad Ishaq Mujeeb Ur Rehman, Muhammad Akram, Muhammad Riaz, Ghulam Rasool, Abdul Hamid Khan, Iqra Saleem, Saba Shamim y Arif Malik. "A review: Mechanism of action of antiviral drugs". International Journal of Immunopathology and Pharmacology 35 (enero de 2021): 205873842110026. http://dx.doi.org/10.1177/20587384211002621.
Texto completoPardee, K. I., P. Ellis, M. Bouthillier, G. HN Towers y C. J. French. "Plant virus inhibitors from marine algae". Canadian Journal of Botany 82, n.º 3 (1 de marzo de 2004): 304–9. http://dx.doi.org/10.1139/b04-002.
Texto completoDe Clercq, E. "Antiviral therapy for human immunodeficiency virus infections." Clinical Microbiology Reviews 8, n.º 2 (abril de 1995): 200–239. http://dx.doi.org/10.1128/cmr.8.2.200.
Texto completoGonzález-Maldonado, Pamela, Nelson Alvarenga, Alberto Burgos-Edwards, Ma Eugenia Flores-Giubi, Javier E. Barúa, Ma Cristina Romero-Rodríguez, Ricardo Soto-Rifo et al. "Screening of Natural Products Inhibitors of SARS-CoV-2 Entry". Molecules 27, n.º 5 (7 de marzo de 2022): 1743. http://dx.doi.org/10.3390/molecules27051743.
Texto completoJones, Gregg S., Fang Yu, Ameneh Zeynalzadegan, Joseph Hesselgesser, Xiaowu Chen, James Chen, Haolun Jin et al. "Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase". Antimicrobial Agents and Chemotherapy 53, n.º 3 (22 de diciembre de 2008): 1194–203. http://dx.doi.org/10.1128/aac.00984-08.
Texto completoGlasky, Alvin J., William R. Roderick y J. C. Holper. "VIRAL SYNTHETASE INHIBITORS AS ANTIVIRAL AGENTS". Annals of the New York Academy of Sciences 130, n.º 1 (16 de diciembre de 2006): 412–18. http://dx.doi.org/10.1111/j.1749-6632.1965.tb12577.x.
Texto completoSerkedjieva, Julia, Lidiya Angelova, Mimi Remichkova y Iskra Ivanova. "Proteinase inhibitors fromStreptomyces with antiviral activity". Journal of Basic Microbiology 46, n.º 6 (diciembre de 2006): 504–12. http://dx.doi.org/10.1002/jobm.200510127.
Texto completoJi, Cheng. "Molecular Factors and Pathways of Hepatotoxicity Associated with HIV/SARS-CoV-2 Protease Inhibitors". International Journal of Molecular Sciences 24, n.º 9 (27 de abril de 2023): 7938. http://dx.doi.org/10.3390/ijms24097938.
Texto completoChang, Kyeong-Ok, Yunjeong Kim, Scott Lovell, Athri Rathnayake y William Groutas. "Antiviral Drug Discovery: Norovirus Proteases and Development of Inhibitors". Viruses 11, n.º 2 (25 de febrero de 2019): 197. http://dx.doi.org/10.3390/v11020197.
Texto completoHerlihy, Koleen J., Joanne P. Graham, Robert Kumpf, Amy K. Patick, Rohit Duggal y Stephanie T. Shi. "Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors". Antimicrobial Agents and Chemotherapy 52, n.º 10 (11 de agosto de 2008): 3523–31. http://dx.doi.org/10.1128/aac.00533-08.
Texto completoBillich, A., D. Scholz, B. Charpiot, H. Gstach, P. Lehr, P. Peichl y B. Rosenwirth. "Potent and Orally Bioavailable HIV-1 Proteinase Inhibitors Containing the 2-aminobenzylstatine Moiety". Antiviral Chemistry and Chemotherapy 6, n.º 5 (octubre de 1995): 327–36. http://dx.doi.org/10.1177/095632029500600507.
Texto completoChan, Renee, Kin Tao, Jiqing Ye, Kevin Lui, Xiao Yang, Cong Ma y Paul Chan. "Inhibition of Influenza Virus Replication by Oseltamivir Derivatives". Pathogens 11, n.º 2 (11 de febrero de 2022): 237. http://dx.doi.org/10.3390/pathogens11020237.
Texto completoHe, Xi, Shuo Quan, Min Xu, Silveria Rodriguez, Shih Lin Goh, Jiajie Wei, Arthur Fridman et al. "Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing". Proceedings of the National Academy of Sciences 118, n.º 15 (25 de marzo de 2021): e2025866118. http://dx.doi.org/10.1073/pnas.2025866118.
Texto completoAfowowe, Tosin Oladipo, Yasuteru Sakurai, Shuzo Urata, Vahid Rajabali Zadeh y Jiro Yasuda. "Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases". Viruses 15, n.º 1 (30 de diciembre de 2022): 105. http://dx.doi.org/10.3390/v15010105.
Texto completoFehrentz, J. A., B. Chomier, E. Bignon, S. Venaud, J. C. Chermann y D. Nisato. "HIV-1 protease inhibitors containing statine : Inhibitory potency and antiviral activity". Biochemical and Biophysical Research Communications 188, n.º 2 (octubre de 1992): 865–72. http://dx.doi.org/10.1016/0006-291x(92)91136-e.
Texto completoChou, Sunwen, Laura C. Van Wechel y Gail I. Marousek. "Effect of Cell Culture Conditions on the Anticytomegalovirus Activity of Maribavir". Antimicrobial Agents and Chemotherapy 50, n.º 7 (julio de 2006): 2557–59. http://dx.doi.org/10.1128/aac.00207-06.
Texto completoDivocha, Valentina y Irina Komarevzeva. "Antiviral proteinase inhibitors of plant and animal origin". Iberoamerican Journal of Medicine 2, n.º 2 (9 de marzo de 2020): 43–48. http://dx.doi.org/10.53986/ibjm.2020.0010.
Texto completoZhao, Xiujuan, Yanyan Wang, Qinghua Cui, Ping Li, Lin Wang, Zinuo Chen, Lijun Rong y Ruikun Du. "A Parallel Phenotypic Versus Target-Based Screening Strategy for RNA-Dependent RNA Polymerase Inhibitors of the Influenza A Virus". Viruses 11, n.º 9 (5 de septiembre de 2019): 826. http://dx.doi.org/10.3390/v11090826.
Texto completo